I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Assistant Director for Patents, Washington, D.C. 20231, on the date shown below. June 5, 2001 PATENT JUN 1 1 2001 Docket No. GC593 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE & TRAD In re Application of Group Art Unit: 1651 Dyson Wade, et al. Serial No.: 09/435,461 Examiner: Meller, M. Filed: November 5, 1999 RECEIVED For: Enzymes Useful for Changing the Properties of Polyester JUN 1 4 2001 **Supplemental TECH CENTER 1600/2900 Information Disclosure Statement Assistant Director for Patents** Washington, DC 20231 Sir: Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. This Information Disclosure Statement: (a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a). (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491. (c) as far as is known to the undersigned, is filed before the mailing date of a

(d) is filed after the first Office Action and more than three months after the

rejection or a notice of allowance, whichever occurs first, and is accompanied by

application filing date or PCT national stage date of entry filing but, as far

as is known to the undersigned, prior to the mailing date of either a final

first Office Action on the merits.

	in 37 (Accou Inform	the fee (\$240) set forth in 37 CFR §1.17(p) r a certification as specified CFR §1.97(e), as checked below. Authorization to charge Deposit nt No. 07-1048 in the amount of \$240.00 to cover the cost of this ation Disclosure Statement is provided in the Transmittal Letter submitted ith in duplicate.
	allowa Transr 07-104 specifi consid	is filed after the mailing date of either a final rejection or a notice of nce, whichever occurred first, and is accompanied by authorization (in the nittal Letter submitted herewith in duplicate) to charge Deposit Account No. 48 the fee (\$240) set forth in 37 CFR §1.17(I)(1) and a certification as ed in 37 CFR §1.97(e), as checked below. This document is to be dered as a petition requesting consideration of the Supplemental nation Disclosure Statement.
[If either of be	oxes (d) or (e) is checked above, the following "certification" under 37 CFR
§1.97(e) may	need to	be completed.] The undersigned certifies that:
	counte	Each item of information contained in the Information Disclosure nent was cited in a communication mailed from a foreign patent office in a repart foreign application not more than three months prior to the filing of formation Disclosure Statement.
	foreign reason	No item of information contained in this Information Disclosure Statement ted in a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making table inquiry, was known to any individual designated in 37 CFR §1.56(c) than three months prior to the filing of this Information Disclosure tent.
A copy of the i	tems o	n Form PTO-1449 is supplied: PCT International Search Report for
PCT/US 00/27917, filed October 10, 2000 with attached patents and publications.		
⊠ eac	h 🗌 n	one only those listed below:
PTO-1449 are	not sur 135,461	blication(s) which are marked with an asterisk (*) on the attached Form oplied because they were previously cited by or submitted to the Office, filed January 22, 2001, and relied upon in this application for an earlier SC 120.
A concise expl	anation	of relevance of the items listed on PTO-1449 is:
	\boxtimes	not given
		given for each listed item
		given for only non-English language listed item(s)

. j

in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: June 5, 2001

Christopher L. Stone Registration No. 35,696

Correspondence Address:

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304 Phone: (650) 846-7555 FAX: (650) 845-6504